prikaz prve stranice dokumenta Inhibitori aromataze (CYP19) : strukturne modifikacije i važnost u terapiji
  Download
PDF 921.77 KB
master's thesis
Inhibitori aromataze (CYP19) : strukturne modifikacije i važnost u terapiji
2019. urn:nbn:hr:171:940351
Grubišić-Čabo, Sara
University of Split
School of Medicine
Pharmacy

Cite this document

Grubišić Čabo, S. (2019). Inhibitori aromataze (CYP19) : strukturne modifikacije i važnost u terapiji (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:940351

Grubišić Čabo, Sara. "Inhibitori aromataze (CYP19) : strukturne modifikacije i važnost u terapiji." Master's thesis, University of Split, School of Medicine, 2019. https://urn.nsk.hr/urn:nbn:hr:171:940351

Grubišić Čabo, Sara. "Inhibitori aromataze (CYP19) : strukturne modifikacije i važnost u terapiji." Master's thesis, University of Split, School of Medicine, 2019. https://urn.nsk.hr/urn:nbn:hr:171:940351

Grubišić Čabo, S. (2019). 'Inhibitori aromataze (CYP19) : strukturne modifikacije i važnost u terapiji', Master's thesis, University of Split, School of Medicine, accessed 12 November 2024, https://urn.nsk.hr/urn:nbn:hr:171:940351

Grubišić Čabo S. Inhibitori aromataze (CYP19) : strukturne modifikacije i važnost u terapiji [Master's thesis]. Split: University of Split, School of Medicine; 2019 [cited 2024 November 12] Available at: https://urn.nsk.hr/urn:nbn:hr:171:940351

S. Grubišić Čabo, "Inhibitori aromataze (CYP19) : strukturne modifikacije i važnost u terapiji", Master's thesis, University of Split, School of Medicine, Split, 2019. Available at: https://urn.nsk.hr/urn:nbn:hr:171:940351

Please login to the repository to save this object to your list.
Metadata
TitleInhibitori aromataze (CYP19) : strukturne modifikacije i važnost u terapiji
Title (english)Aromatase inhibitors (CYP19) : structural modifications and importance in therapy
AuthorSara Grubišić-Čabo
MentorMarica Medić-Šarić (mentor)
Committee memberMaja Valić (predsjednik povjerenstva)
Committee memberDavorka Sutlović (član povjerenstva)
Committee memberMarica Medić-Šarić (član povjerenstva)
GranterUniversity of Split
School of Medicine
(Pharmacy)
Split
Defense date and country2019-04-29, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Pharmacy
Abstract
Cilj ovog diplomskog rada je proučavanje mogućeg nastanka karcinoma dojke, uzrokovanog metaboličkim promjenama na estrogenim hormonima, a pod utjecajem enzimskih sustava koji u tim reakcijama sudjeluju. Prikazani su glavni metabolički putovi estrogenih hormona kao i metaboličke promjene lijekova koji se koriste u liječenju karcinoma dojke s posebnim naglaskom na inhibitore aromataze. Opisane su reakcije I. i II. faze biotransformacije kroz koje prolazi najpotentnija treća generacija inhibitora aromataze – anastrozol, letrozol i eksemestan. Anastrozol podliježe N-dealkilaciji, hidroksilaciji i glukuronidaciji. Letrozol podliježe N-dealkilaciji, te pod utjecajem enzima CYP ostaje produkt koji se zove karbinol koji potom podliježe procesu glukuronidacije. Eksemestan podliježe redukciji keto skupine u položaju 17, oksidaciji metilenske grupe u položaju 6, te glukuronidaciji. Opisane su i najvažnije interakcije anastrozola, letrozola i eksemestana.
Abstract (english)
The aim of this graduate thesis is to study the possible emergence of breast cancer caused by metabolic changes on estrogen hormones and under the influence of the enzymatic systems involved in these reactions. The main metabolic pathways of estrogenic hormones have been described as well as the metabolic changes of the drugs used in the treatment of breast cancer with particular emphasis on aromatase inhibitors. The reactions of biotransformation of phases I and II of the most potent third generation of aromatase inhibitors - anastrozole, letrozole and exemestane have been described. Anastrozole is subjected to N-dealkylation, hydroxylation and glucuronidation. Letrozole is subjected to N-dealkylation, and under the influence of the CYP enzymes remains a product called carbinol which is then subjected to the glucuronidation process. The exemestane is subjected to reduction of the keto group at position 17, oxidation of the methylene group at position 6, and glucuronidation. The most important interactions of anastrozole, letrozole and exemestane are also described.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:171:940351
Study programmeTitle: Pharmacy
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2019-11-29 16:06:22